Program
VX-993
A development code. Also written as “14C-VX-993”.
Its studies are mostly in Pain · Neuralgia · Acute Pain, led by Vertex Pharmaceuticals.
Furthest: phase 2, since Sep 27, 202410 company-led studies, 1 open or runningNext primary completion: Mar 25, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vertex Pharmaceuticals | 101 open or running | phase 2since Sep 27, 2024 | Dec 7, 2022 | Mar 25, 2027phase 2 · NCT06619860 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 7, 2022First study: phase 1 study in PainFirst studyNCT05653323 · 70 enrolled · United Kingdom
- Dec 20, 2023Phase 1 study in PainNCT06226454 · 39 enrolled · United States
- Apr 25, 20242 phase 1 studies in PainNCT06392659, NCT06394167
- May 14, 2024Phase 1 study in PainNCT06420765 · 92 enrolled · United Kingdom
- Jul 12, 20242 phase 1 studies in PainNCT06508762, NCT06523595
- Sep 27, 20242 phase 2 studiesNCT06619860, NCT06619847
- Mar 14, 2025Phase 1 study in PainNCT06886269 · 8 enrolled · United States
Ahead
- Mar 25, 2027Primary completion: phase 2 study in Diabetic Peripheral Neuropathic PainNCT06619860
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06886269Pain · United States | 1 | Completed | May 17, 2025 | 8 |
| NCT06619860Diabetic Peripheral Neuropathic Pain · United States, Canada, France and more | 2 | Recruiting | Mar 25, 2027 | 300 |
| NCT06619847Acute Pain · United States | 2 | Completed | May 27, 2025 | 367 |
| NCT06523595Pain · United States | 1 | Completed | Dec 31, 2024 | 31 |
| NCT06508762Pain · United States | 1 | Completed | Sep 10, 2024 | 24 |
| NCT06420765Pain · United Kingdom | 1 | Completed | Mar 22, 2025 | 92 |
| NCT06394167Pain · United States | 1 | Completed | Feb 18, 2025 | 88 |
| NCT06392659Pain · United Kingdom | 1 | Completed | Jul 2, 2024 | 42 |
| NCT06226454Pain · United States | 1 | Completed | Jun 12, 2024 | 39 |
| NCT05653323Pain · United Kingdom | 1 | Completed | Sep 12, 2023 | 70 |
How it is read
Names in the registry
- “VX-993”, 9 entries
- “14C-VX-993”, 1 entry
Codes read as this program: VX993.
Conditions, from the studies’ own filings
- Pain, 8 studies
- Neuralgia, 1 study
- Acute Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.